Jansen Michaela, Potschka Heidrun, Brandt Claudia, Löscher Wolfgang, Dannhardt Gerd
Institut für Pharmazie, Johannes Gutenberg-Universität, D-55099 Mainz, Germany.
J Med Chem. 2003 Jan 2;46(1):64-73. doi: 10.1021/jm020955n.
A novel series of C-3 substituted 4,6-dichloroindole-2-carboxylic acids was synthesized to investigate the influence of different hydrogen-bond donor and acceptor groups at this specific position on the affinity to the glycine site of the NMDA receptor. These novel 3-indolylmethyl derivatives with ring-open (amines, sulfonamides, amides, ureas) and cyclic substituents (imidazolidin-2-ones, (thio)hydantoins) led to the discovery that compounds bearing a hydantoin substituent at the C-3 position of the indole nucleus are the most promising ones. In this series the hydantoins, ureas, and imidazolidin-2-ones were identified as very potent inhibitors of the binding of the glycine site specific ligand [(3)H]MDL 105,519 to pig cortical brain membranes. Since the hydantoins can be produced via a versatile synthetic approach, further amendments of the hydantoin-substituted compounds were conducted to elucidate the influence of aromatic and aliphatic moieties at position 3 of the hydantoin as well as of sterically hindered compounds (5-substituted hydantoins). On the basis of the pharmacological data obtained in displacement experiments with [(3)H]MDL 105,519 and the emerging structure-activity relationships, we confirm the existing pharmacophore model that suggests a hydrogen-bond acceptor and an aromatic substituent at position 3 of the indole as the key features for high affinity. Log P values indicate brain permeability and selected compounds showed anticonvulsant activity in vivo. Binding studies for the sodium channel (site 2) were also performed on some selected compounds.
合成了一系列新型的C-3位取代的4,6-二氯吲哚-2-羧酸,以研究该特定位置上不同的氢键供体和受体基团对与NMDA受体甘氨酸位点亲和力的影响。这些具有开环(胺、磺酰胺、酰胺、脲)和环状取代基(咪唑烷-2-酮、(硫)乙内酰脲)的新型3-吲哚基甲基衍生物导致发现,在吲哚核的C-3位置带有乙内酰脲取代基的化合物是最有前景的。在该系列中,乙内酰脲、脲和咪唑烷-2-酮被确定为甘氨酸位点特异性配体[(3)H]MDL 105,519与猪脑皮层膜结合的非常有效的抑制剂。由于乙内酰脲可以通过通用的合成方法制备,因此对乙内酰脲取代的化合物进行了进一步修饰,以阐明乙内酰脲3位上芳香族和脂肪族部分以及空间位阻化合物(5-取代乙内酰脲)的影响。基于用[(3)H]MDL 105,519进行置换实验获得的药理学数据以及新出现的构效关系,我们证实了现有的药效团模型,该模型表明吲哚3位上的氢键受体和芳香族取代基是高亲和力的关键特征。Log P值表明脑通透性,所选化合物在体内显示出抗惊厥活性。还对一些选定的化合物进行了钠通道(位点2)的结合研究。